An Israeli biotech is looking to make its name in the jam-packed CD47 space. Is bifunctionality the answer?
Jerusalem’s KAHR Medical had been working on fusion proteins for autoimmune disorders for about 10 years, before “issues in development” spurred then-new CEO Yaron Pereg to change gears in 2017.
“We had done our gap analysis and thought, ‘This is a very cool technology and very interesting platform, why won’t we start from scratch, do things different and also select more novel targets?’” he said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.